{"entity":{"id":"alice-chen","kind":"person","name":"Alice P. Chen","aka":[],"tldr":"NCI oncologist who led the trial that showed atezolizumab produces lasting responses in alveolar soft part sarcoma, the first approved treatment for this rare cancer.","summary":"Alice Chen leads early clinical trials at the National Cancer Institute's Division of Cancer Treatment and Diagnosis and co-led the NCI-MATCH precision medicine trial. She was first author of the 2023 New England Journal of Medicine report of the phase 2 trial in which the PD-L1 antibody atezolizumab produced durable responses in about a quarter of patients with advanced alveolar soft part sarcoma, the basis of the drug's approval for the disease.","asOf":"2026-09-18","links":[],"tags":["sarcoma","rare-cancers","immunotherapy","trialist"],"related":[],"cancers":["alveolar-soft-part-sarcoma","sarcoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["nci"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-atezolizumab-alveolar-soft-part-sarcoma-chen-nejm-2023"],"journals":[],"dependsOn":[],"notes":[],"role":"Medical oncologist, Division of Cancer Treatment and Diagnosis, National Cancer Institute","institutionId":"nci","specialisms":["Early-phase trials","Rare cancers","Precision oncology trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Chen%5BAuthor%5D"}],"papers":[]},"route":"/people/alice-chen/","neighbours":{"cancer":[{"id":"alveolar-soft-part-sarcoma","kind":"cancer","name":"Alveolar soft part sarcoma","route":"/cancers/alveolar-soft-part-sarcoma/"},{"id":"sarcoma","kind":"cancer","name":"Sarcomas (soft tissue, bone, GIST)","route":"/cancers/sarcoma/"}],"institution":[{"id":"nci","kind":"institution","name":"National Cancer Institute (NIH)","route":"/institutions/nci/"}],"paper":[{"id":"paper-atezolizumab-alveolar-soft-part-sarcoma-chen-nejm-2023","kind":"paper","name":"Atezolizumab for advanced alveolar soft part sarcoma","route":"/key-papers/paper-atezolizumab-alveolar-soft-part-sarcoma-chen-nejm-2023/"}]}}